2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosisMike P. Wattjes, Olga Ciccarelli, Daniel S. Reich et al.|The Lancet Neurology|2021Cited by 646
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce Cree, Piotr Sokolowski, Gary Cutter et al.|The Lancet Neurology|2020Cited by 104
2024 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosisFrederik Barkhof, Àlex Rovira, Daniel S. Reich et al.|The Lancet Neurology|2025Cited by 64
Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset PopulationsLe H. Hua, Emmanuelle Waubant, Cheryl Hemingway et al.|JAMA Neurology|2024Cited by 16
Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and AustralasiaLilyana Amezcua, Walter Royal, Dalia Rotstein et al.|The Lancet Neurology|2024Cited by 11